Title
Subscribe to the Magazine for free
Subscribe for free to keep reading! If you are already subscribed, enter your email address to log back in.
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Are you a healthcare practitioner?
Thanks for subscribing!
Oops! Something went wrong while submitting the form.

Biologic Treatments for Psoriasis: Targeting the Immune System

Written By

Why This Was Updated?

Our specialists regularly review advancements in health and wellness, ensuring our articles are updated with the newest information as it becomes accessible.
Medically Reviewed by
Dr.
Ayesha Bryant
MSPH, MD

Psoriasis is a chronic autoimmune skin condition that goes beyond the surface, affecting various aspects of life with its persistent symptoms like red, scaly patches, itching, and discomfort. It’s not just about the visible marks on the skin; it’s about the immune system mistakenly attacking healthy skin cells, leading to inflammation and rapid skin cell turnover.

Biologic treatments have emerged as a promising option for those looking for more effective ways to manage psoriasis. Unlike traditional treatments that mainly address the symptoms, biologics directly target the immune system, helping reduce the inflammation that drives psoriasis. This article aims to provide a clear understanding of how biologic treatments can play an important role in managing psoriasis.

[signup]

Understanding the Role of the Immune System in Psoriasis

Psoriasis is an autoimmune condition where the immune system, which normally protects the body from infections, mistakenly attacks healthy skin cells. This misguided immune response speeds up the growth cycle of skin cells, leading to the buildup of red, scaly patches on the skin. The inflammation caused by this immune attack is a hallmark of psoriasis, making it more than just a skin problem but a reflection of deeper immune system dysfunction.

Several key immune pathways play a role in the development and progression of psoriasis. Among the most important are cytokines, proteins that help regulate the immune response. Certain cytokines, like TNF-alpha, IL-17, and IL-23, are overactive in psoriasis, driving the inflammatory process. These cytokines contribute to the rapid turnover of skin cells and the characteristic inflammation seen in psoriasis.

Modulating the immune system effectively treats psoriasis by addressing the condition at its source. By targeting specific immune responses, biologic treatments can reduce inflammation and the excessive skin cell production that causes psoriasis. This approach helps clear the skin and reduces other symptoms like itching and pain, providing a more comprehensive management strategy.

What Are Biologic Treatments?

Biologics are a class of medications derived from living cells, such as proteins, that are engineered to target specific components of the immune system. Unlike traditional drugs that are chemically synthesized, biologics are complex and specifically designed to interfere with particular pathways that contribute to autoimmune conditions like psoriasis.

Traditional systemic treatments for psoriasis, such as methotrexate and cyclosporine, broadly suppress the immune system. While effective, they can also affect other parts of the immune system, leading to more side effects. 

In contrast, biologics are more targeted, focusing on specific molecules involved in the inflammatory process. This targeted approach allows biologics to reduce symptoms with potentially fewer side effects than traditional systemic therapies.

Types of Biologic Treatments for Psoriasis

Biologic treatments for psoriasis include TNF-alpha inhibitors, IL-12/23 inhibitors, IL-17 inhibitors, and IL-23 inhibitors. Each targets specific immune pathways to reduce inflammation and improve skin symptoms.

1. TNF-alpha Inhibitors

How They Work:

TNF-alpha inhibitors block the activity of tumor necrosis factor-alpha (TNF-alpha), a cytokine that plays a central role in the inflammatory process associated with psoriasis. By inhibiting TNF-alpha, these treatments help reduce inflammation and the formation of psoriatic plaques.

Examples:

  • Etanercept (Enbrel)
  • Infliximab (Remicade)
  • Adalimumab (Humira)

Efficacy and Use:

TNF-alpha inhibitors are effective for moderate to severe psoriasis, especially in cases where other treatments have not succeeded. They are also used for psoriatic arthritis, relieving joint pain and swelling.

Potential Side Effects:

Common risks include increased susceptibility to infections and potential heart failure. Some patients may experience a paradoxical worsening of psoriasis.

2. IL-12/23 Inhibitors

How They Work:

These inhibitors target interleukin-12 (IL-12) and interleukin-23 (IL-23), cytokines that activate immune cells and contribute to psoriasis inflammation.

Examples:

  • Ustekinumab (Stelara)

Efficacy and Use:

IL-12/23 inhibitors are used for plaque psoriasis and psoriatic arthritis, demonstrating effectiveness in long-term management and symptom control.

Potential Side Effects:

Potential side effects include an increased risk of infections and rare but serious conditions such as reversible posterior leukoencephalopathy syndrome (RPLS).

3. IL-17 Inhibitors

How They Work:

IL-17 inhibitors block interleukin-17 (IL-17), a cytokine crucial in developing psoriasis plaques and inflammation.

Examples:

  • Secukinumab (Cosentyx)
  • Ixekizumab (Taltz)
  • Brodalumab (Siliq)

Efficacy and Use:

These inhibitors are highly effective for moderate to severe psoriasis, often improving skin symptoms rapidly.

Potential Side Effects:

Risks include potential infections and the possibility of exacerbating inflammatory bowel disease.

4. IL-23 Inhibitors

How They Work:

IL-23 inhibitors specifically target interleukin-23, reducing the activity of immune cells that drive psoriasis.

Examples:

  • Guselkumab (Tremfya)
  • Tildrakizumab (Ilumya)
  • Risankizumab (Skyrizi)

Efficacy and Use:

IL-23 inhibitors effectively treat moderate to severe psoriasis, focusing on achieving long-term skin clearance.

Potential Side Effects:

Potential side effects include infections and elevated liver enzymes.

Benefits of Biologic Treatments

Biologics offer targeted action, high efficacy in achieving skin clearance, and effective long-term management of psoriasis with fewer flare-ups.

Targeted Action

Biologic treatments offer a more precise approach by targeting specific immune system components involved in psoriasis. This targeted action helps to minimize the broader immune suppression seen with traditional treatments, reducing side effects while effectively controlling symptoms.

High Efficacy

Biologics are known for their high efficacy. They often achieve significant skin clearance and improve the quality of life for those with moderate to severe psoriasis. They can quickly reduce symptoms, making them a preferred option for many.

Long-Term Management

One of the key benefits of biologic treatments is their effectiveness in long-term management. By reducing the frequency and severity of flare-ups, biologics help maintain sustained skin improvement and provide better control over psoriasis symptoms over time. This long-term stability can be life-changing for those managing chronic psoriasis.

Considerations Before Starting Biologic Therapy

Biologic treatments are typically recommended for individuals with moderate to severe psoriasis who have not responded well to other treatments, such as topical therapies or traditional systemic medications. Candidates often have psoriasis covering more than 5% to 10% of their body or have psoriasis in challenging areas like the face, hands, or feet.

Conduct pre-treatment screenings to ensure patient safety before starting biologic therapy. This includes testing for infections such as tuberculosis, assessing liver function, and evaluating other health factors that might affect treatment. 

Biologic treatments can have both common and serious side effects. Common side effects include injection site reactions, headaches, and flu-like symptoms. More serious risks involve increased susceptibility to infections, allergic reactions, and rare conditions such as reversible posterior leukoencephalopathy syndrome (RPLS) with certain biologics.

Cost can also be a concern, as biologics are expensive, but insurance coverage and patient assistance programs can help manage expenses.

Administration and Monitoring of Biologics

Biologics are administered either through subcutaneous injections or intravenous infusions. Subcutaneous injections can often be done at home using prefilled syringes or auto-injectors, while intravenous infusions are typically conducted in a clinical setting.

The dosing schedule for biologics varies depending on the specific medication. Some biologics require weekly or biweekly administration, while others may be administered every few months. For example, ustekinumab is often given every 12 weeks after initial doses.

Regular monitoring is essential to assess the efficacy of the treatment and manage any side effects. Patients typically have follow-up appointments every few weeks to months, depending on their overall health and the specific biologic used. This allows healthcare providers to make necessary adjustments to the treatment plan to ensure optimal outcomes.

Managing Side Effects and Complications

While biologic treatments are effective, they can have side effects that need careful management. Understanding how to handle these side effects and knowing when to seek medical help are important steps in maintaining a safe and successful treatment journey.

Common Side Effects

Biologic treatments for psoriasis can cause common side effects such as injection site reactions, fatigue, and mild infections. Here are some ways to manage these:

  • Injection Site Reactions: These can include redness, swelling, or pain at the injection site. Applying a cold compress after the injection and rotating injection sites can help minimize discomfort.
  • Fatigue: Ensuring adequate rest, maintaining a balanced diet, and engaging in regular physical activity can help manage fatigue.
  • Mild Infections: Good hygiene, such as frequent hand washing, can reduce the risk of infections. If symptoms persist or worsen, contact your healthcare provider.

Serious Side Effects

Serious side effects of biologics, though rare, require immediate medical attention. These include:

  • Severe Infections: Symptoms like fever, chills, or persistent cough should prompt a visit to the doctor.
  • Allergic Reactions: Signs such as difficulty breathing, swelling of the face or throat, or severe rash need urgent care.
  • Unexplained Symptoms: Any new or unusual symptoms should be promptly reported to a healthcare provider.

Long-Term Safety

Ongoing monitoring and communication with healthcare providers are crucial to ensure the safe use of biologics over time. Regular follow-up appointments allow for the assessment of treatment efficacy and the management of any emerging side effects. Blood tests and other screenings may be conducted periodically to monitor for potential complications.

Living with Psoriasis on Biologic Treatments

Biologic treatments can significantly improve daily functioning by reducing psoriasis symptoms. Patients often experience better skin clearance, which enhances their ability to participate in work and social activities and improves their quality of life.

Adhering to treatment schedules and maintaining regular follow-up appointments are essential for achieving optimal outcomes with biologic therapy. Consistent use of biologics helps manage symptoms effectively and prevent flare-ups.

Maintaining a healthy lifestyle is important to support the success of biologic treatments. This includes:

  • Diet: A balanced diet can help manage weight and reduce inflammation.
  • Exercise: Regular physical activity can improve overall health and reduce stress.
  • Stress Management: Techniques such as meditation or yoga can help manage stress, which can exacerbate psoriasis symptoms.

Patients can enhance their treatment outcomes and overall well-being by integrating these lifestyle changes with biologic therapy.

[signup]

Key Takeaways

  • Psoriasis is an autoimmune condition in which the immune system mistakenly attacks healthy skin cells. This causes inflammation and rapid cell turnover, leading to red, scaly patches on the skin.
  • Biologic treatments target specific immune pathways involved in psoriasis, such as TNF-alpha, IL-12/23, IL-17, and IL-23, offering a more precise approach than traditional therapies by reducing inflammation and symptoms with potentially fewer side effects.
  • Types of biologic treatments include TNF-alpha inhibitors (e.g., Etanercept), IL-12/23 inhibitors (e.g., Ustekinumab), IL-17 inhibitors (e.g., Secukinumab), and IL-23 inhibitors (e.g., Guselkumab), each targeting different cytokines involved in the disease.
  • Biologics are highly effective for moderate to severe psoriasis, providing significant skin clearance, long-term symptom control, and improved quality of life by reducing flare-ups and the severity of symptoms.
The information provided is not intended to be a substitute for professional medical advice. Always consult with your doctor or other qualified healthcare provider before taking any dietary supplement or making any changes to your diet or exercise routine.
Learn More
No items found.

Lab Tests in This Article

No lab tests!

AAD. (n.d.). Psoriasis treatment: Biologics. Www.aad.org. https://www.aad.org/public/diseases/psoriasis/treatment/medications/biologics

Baliwag, J., Barnes, D. H., & Johnston, A. (2015). Cytokines in psoriasis. Cytokine, 73(2), 342–350. https://doi.org/10.1016/j.cyto.2014.12.014

Branch, N. S. C. and O. (2017, April 12). Psoriasis. National Institute of Arthritis and Musculoskeletal and Skin Diseases. https://www.niams.nih.gov/health-topics/psoriasis#:~:text=Psoriasis%20is%20an%20immune%2Dmediated

Cather, J. C., & Crowley, J. J. (2014). Use of Biologic Agents in Combination with Other Therapies for the Treatment of Psoriasis. American Journal of Clinical Dermatology, 15(6), 467–478. https://doi.org/10.1007/s40257-014-0097-1

Clark, Kirby, Morris, Davison, Zaki, Emerson, Saihan, Chalmers, N.barker, Allen, & Griffiths. (1999). Combination treatment with methotrexate and cyclosporin for severe recalcitrant psoriasis. British Journal of Dermatology, 141(2), 279–282. https://doi.org/10.1046/j.1365-2133.1999.02976.x

DePorto, T. (2023, February 1). The Gut’s Role in The Development and Treatment of Psoriasis: A Integrative Medicine Approach. Rupa Health. https://www.rupahealth.com/post/the-guts-role-in-the-development-and-treatment-of-psoriasis-a-integrative-medicine-approach

Dhabale, A., & Nagpure, S. (2022). Types of Psoriasis and Their Effects on the Immune System. Cureus, 14(9), e29536. https://doi.org/10.7759/cureus.29536

Dogra, S., & Khullar, G. (2013, June 30). Indian Journal of Dermatology, Venereology and Leprology - Tumor necrosis factor-α antagonists: Side effects and their management. Indian Journal of Dermatology, Venereology and Leprology. https://ijdvl.com/tumor-necrosis-factor-antagonists-side-effects-and-their-management/

Emer, J. J., Frankel, A., & Zeichner, J. A. (2010). A Practical Approach to Monitoring Patients on Biological Agents for the Treatment of Psoriasis. The Journal of Clinical and Aesthetic Dermatology, 3(8), 20–26. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2945861/

Ergen, E. N., & Yusuf, N. (2018). Inhibition of interleukin-12 and/or interleukin-23 for the treatment of psoriasis: What is the evidence for an effect on malignancy? Experimental Dermatology, 27(7), 737–747. https://doi.org/10.1111/exd.13676

Huang, X., Haojie Shentu, He, Y., Lai, H., Xu, C., Chen, M., & Zhu, H. (2023). Efficacy and safety of IL-23 inhibitors in the treatment of psoriatic arthritis: a meta-analysis based on randomized controlled trials. Immunologic Research, 71(4), 505–515. https://doi.org/10.1007/s12026-023-09366-4

Kearns, D. G., Uppal, S., Chat, V. S., & Wu, J. J. (2021). Comparison of Guidelines for the Use of Interleukin-17 Inhibitors for Psoriasis in the United States, Britain, and Europe: A Critical Appraisal and Comprehensive Review. The Journal of Clinical and Aesthetic Dermatology, 14(6), 55–59. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8594534/

Khakham, C. (2023a, May 22). A Comprehensive Review of Complementary and Integrative Medicine Approaches to the Management of Psoriatic Arthritis. Rupa Health. https://www.rupahealth.com/post/a-comprehensive-review-of-complementary-and-integrative-medicine-approaches-to-the-management-of-psoriatic-arthritis

Khakham, C. (2023b, June 8). Exploring the Complexities of Autoimmune Diseases: Unraveling Mechanisms, Risk Factors, and Integrative Approaches to Testing, Diagnosis, and Treatment. Rupa Health. https://www.rupahealth.com/post/understanding-autoimmune-diseases-mechanisms-and-risk-factors

Ko, S.-H., Chi, C.-C., Yeh, M.-L., Wang, S.-H., Tsai, Y.-S., & Hsu, M.-Y. (2019). Lifestyle changes for treating psoriasis. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd011972.pub2

Koutruba, N., Emer, J., & Lebwohl, M. (2010). Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis. Therapeutics and Clinical Risk Management, 6, 123–141. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2857612/

Levine, D., & Strober, B. E. (2010). The Treatment of Moderate-to-Severe Psoriasis: Prescreening and Monitoring Psoriatic Patients on Biologics. Seminars in Cutaneous Medicine and Surgery, 29(1), 28–34. https://doi.org/10.1016/j.sder.2010.02.003

Li, S. J., Perez-Chada, L. M., & Merola, J. F. (2018). TNF Inhibitor-Induced Psoriasis: Proposed Algorithm for Treatment and Management. Journal of Psoriasis and Psoriatic Arthritis, 4(2), 70–80. https://doi.org/10.1177/2475530318810851

Liu, J., Wang, X., Yu, X.-L., Lin, Z.-M., Yuan, L.-Y., & Yang, B. (2023). Effects of Biologics on Mental Health and Health-Related Quality of Life in Patients With Psoriasis: A Repeated Cross-Sectional Survey in Chinese Population. International Journal of Dermatology and Venereology. https://doi.org/10.1097/jd9.0000000000000343

Lowes, M. A., Suárez-Fariñas, M., & Krueger, J. G. (2014). Immunology of Psoriasis. Annual Review of Immunology, 32(1), 227–255. https://doi.org/10.1146/annurev-immunol-032713-120225

Piragine, E., Petri, D., Martelli, A., Janowska, A., Dini, V., Romanelli, M., Calderone, V., & Lucenteforte, E. (2022). Adherence and Persistence to Biological Drugs for Psoriasis: Systematic Review with Meta-Analysis. Journal of Clinical Medicine, 11(6), 1506. https://doi.org/10.3390/jcm11061506

Raina, S., Mahesh, D. M., G Rajendra, & Chauhan, N. S. (2012). Reversible posterior leukoencephalopathy syndrome. Journal of Neurosciences in Rural Practice, 03(02), 222–224. https://doi.org/10.4103/0976-3147.98262

Robinson, S., Tang Min Moon, Tey Kwee Eng, Teoh Tze Yuen, Tang Jyh Jong, Latha Selvarajah, Tan Wooi Chiang, Teh Yeon Chiat, Tiong, J., Harini Chinthapatla, Shu Kee Eng, & Suganthi Thevarajah. (2023). Dermatology Life Quality Index in Patients with Psoriasis Treated with Biologic Versus Non-biologic Treatment in Malaysia: A Retrospective Cross-Sectional Study. Drugs - Real World Outcomes, 10(2), 291–298. https://doi.org/10.1007/s40801-023-00359-1

Rodgers, M., Epstein, D., L Bojke, Yang, H., Craig, D., Fonseca, T., Myers, L., Bruce, I., Chalmers, R., S Bujkiewicz, Lai, M., Cooper, N., Abrams, K., Spiegelhalter, D., Sutton, A., M Sculpher, & N Woolacott. (2011, February). Etanercept, Infliximab and Adalimumab for the Treatment of Psoriatic Arthritis: A Systematic Review and Economic Evaluation. Nih.gov; NIHR Journals Library. https://www.ncbi.nlm.nih.gov/books/NBK109482/

Singh, J. A., Wells, G. A., Christensen, R., Tanjong Ghogomu, E., Maxwell, L. J., MacDonald, J. K., Filippini, G., Skoetz, N., Francis, D. K., Lopes, L. C., Guyatt, G. H., Schmitt, J., La Mantia, L., Weberschock, T., Roos, J. F., Siebert, H., Hershan, S., Cameron, C., Lunn, M. P., & Tugwell, P. (2011). Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd008794.pub2

ten Bergen, L. L., Petrovic, A., Krogh Aarebrot, A., & Appel, S. (2020). The TNF/IL‐23/IL‐17 axis—Head‐to‐head trials comparing different biologics in psoriasis treatment. Scandinavian Journal of Immunology, 92(4). https://doi.org/10.1111/sji.12946

Wang, J., Wang, C., Liu, L., Hong, S., Ru, Y., Sun, X., Chen, J., Zhang, M., Lin, N., Li, B., & Li, X. (2023). Adverse events associated with anti-IL-17 agents for psoriasis and psoriatic arthritis: a systematic scoping review. Frontiers in Immunology, 14. https://doi.org/10.3389/fimmu.2023.993057

Yang, K., Oak, A. S. W., & Elewski, B. E. (2020). Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review. American Journal of Clinical Dermatology, 22(2), 173–192. https://doi.org/10.1007/s40257-020-00578-0

Yost, J., & Gudjonsson, J. (2009). The role of TNF inhibitors in psoriasis therapy: new implications for associated comorbidities. F1000 Medicine Reports. https://doi.org/10.3410/m1-30

Zhang. (2017). Patient Preference for Dosing Frequency Based on Prior Biologic Experience. Journal of Drugs in Dermatology : JDD, 16(3). https://pubmed.ncbi.nlm.nih.gov/28301617/

Subscribe to the Magazine for free to keep reading!
Subscribe for free to keep reading, If you are already subscribed, enter your email address to log back in.
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Are you a healthcare practitioner?
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
See All Magazine Articles
Trusted Source
Rupa Health
Medical Education Platform
Visit Source
American Cancer Society
Foundation for Cancer Research
Visit Source
National Library of Medicine
Government Authority
Visit Source
Journal of The American College of Radiology
Peer Reviewed Journal
Visit Source
National Cancer Institute
Government Authority
Visit Source
World Health Organization (WHO)
Government Authority
Visit Source
The Journal of Pediatrics
Peer Reviewed Journal
Visit Source
CDC
Government Authority
Visit Source
Office of Dietary Supplements
Government Authority
Visit Source
National Heart Lung and Blood Institute
Government Authority
Visit Source
National Institutes of Health
Government Authority
Visit Source
Clinical Infectious Diseases
Peer Reviewed Journal
Visit Source
Brain
Peer Reviewed Journal
Visit Source
The Journal of Rheumatology
Peer Reviewed Journal
Visit Source
Journal of the National Cancer Institute (JNCI)
Peer Reviewed Journal
Visit Source
Journal of Cardiovascular Magnetic Resonance
Peer Reviewed Journal
Visit Source
Hepatology
Peer Reviewed Journal
Visit Source
The American Journal of Clinical Nutrition
Peer Reviewed Journal
Visit Source
The Journal of Bone and Joint Surgery
Peer Reviewed Journal
Visit Source
Kidney International
Peer Reviewed Journal
Visit Source
The Journal of Allergy and Clinical Immunology
Peer Reviewed Journal
Visit Source
Annals of Surgery
Peer Reviewed Journal
Visit Source
Chest
Peer Reviewed Journal
Visit Source
The Journal of Neurology, Neurosurgery & Psychiatry
Peer Reviewed Journal
Visit Source
Blood
Peer Reviewed Journal
Visit Source
Gastroenterology
Peer Reviewed Journal
Visit Source
The American Journal of Respiratory and Critical Care Medicine
Peer Reviewed Journal
Visit Source
The American Journal of Psychiatry
Peer Reviewed Journal
Visit Source
Diabetes Care
Peer Reviewed Journal
Visit Source
The Journal of the American College of Cardiology (JACC)
Peer Reviewed Journal
Visit Source
The Journal of Clinical Oncology (JCO)
Peer Reviewed Journal
Visit Source
Journal of Clinical Investigation (JCI)
Peer Reviewed Journal
Visit Source
Circulation
Peer Reviewed Journal
Visit Source
JAMA Internal Medicine
Peer Reviewed Journal
Visit Source
PLOS Medicine
Peer Reviewed Journal
Visit Source
Annals of Internal Medicine
Peer Reviewed Journal
Visit Source
Nature Medicine
Peer Reviewed Journal
Visit Source
The BMJ (British Medical Journal)
Peer Reviewed Journal
Visit Source
The Lancet
Peer Reviewed Journal
Visit Source
Journal of the American Medical Association (JAMA)
Peer Reviewed Journal
Visit Source
Pubmed
Comprehensive biomedical database
Visit Source
Harvard
Educational/Medical Institution
Visit Source
Cleveland Clinic
Educational/Medical Institution
Visit Source
Mayo Clinic
Educational/Medical Institution
Visit Source
The New England Journal of Medicine (NEJM)
Peer Reviewed Journal
Visit Source
Johns Hopkins
Educational/Medical Institution
Visit Source